Statistics on Biotechnology Use  
Results by sector of operation
Company sector.  Biotechnology results by main variables by whichever Biotechnology activities are the main ones, secondary or a tool necessary for production
Units: specified in variables

;Total;Main;Secondary dwellings;Tool;
Companies that carry out R&D in Biotechnology;1,133;603;173;357;
%Companies according to biotechnology used: Genetic code;33;39;28;25;
%Companies according to biotechnology used: Functional units;41;44;39;36;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;24;29;19;17;
%Companies according to biotechnology used: Bioprocesses;50;45;42;61;
%Companies according to biotechnology used: Sub-cellular organisms;6;8;5;3;
%Companies according to biotechnology used: Bio-computing;24;33;19;12;
%Companies according to biotechnology used: Nanobiotechnology;13;17;15;6;
%Companies according to biotechnology used: Other;14;16;16;11;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45;59;41;24;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;18;21;14;13;
%Company by field(s) of ultimate application of biotechnology use: Food products;31;25;28;43;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;22;19;27;26;
%Company by field(s) of ultimate application of biotechnology use: Environment;14;11;22;13;
%Company by field(s) of ultimate application of biotechnology use: Industry;12;13;16;8;
Personnel in R&D in biotechnology (no. of persons);11,510;6,862;1,521;3,127;
Personnel in R&D in biotechnology (no. of persons): Researchers;6,202;3,759;900;1,543;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;5,308;3,103;621;1,584;
Personnel in R&D in biotechnology (no. of persons): women;6,389;4,015;750;1,624;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;3,304;2,079;442;783;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;3,086;1,937;308;841;
Personnel in R&D in biotechnology (FTE);8,236.9;5,430.2;989.7;1,817.0;
Personnel in R&D in biotechnology (FTE): Researchers;4,596.1;3,001.4;642.6;952.1;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;3,640.8;2,428.8;347.1;864.9;
Personnel in R&D in biotechnology (FTE): women;4,698.5;3,180.1;503.1;1,015.3;
Personnel in R&D in biotechnology (FTE): (women) Researchers;2,512.5;1,684.7;323.4;504.4;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;2,186.0;1,495.4;179.7;510.9;
Internal expenditure on R&D (thousands of euros);769,431;541,881;63,951;163,599;
1) By nature of the expense: Current expenses;719,715;502,430;60,603;156,683;
1.1) Remuneration to researchers;221,447;151,282;26,154;44,011;
1.2) Remuneration to technicians and assistants;122,809;83,753;10,469;28,587;
1.3) Other current expenses;375,459;267,396;23,979;84,084;
2) By nature of the expense: Capital expenses;49,715;39,451;3,348;6,916;
2.1) Land and buildings;9,521;7,987;676;858;
2.2) Equipment and instruments;30,466;22,742;2,475;5,248;
2.3) Acquisition of specific R+D software;1,810;1,212;89;509;
2.4) Otros productos de propiedad intelectual específicos para I+D;7,919;7,510;108;301;
1.1) By origin of the funds: Own funds;490,913;347,382;40,321;103,210;
1.2) By origin of the funds: From companies;82,548;62,516;5,356;14,676;
1.3) By origin of the funds: Public Administration funds;96,809;67,645;12,905;16,259;
1.4) By origin of the funds: From Universities;197;193;0;4;
1.5) By origin of the funds: From non profit private institutions;4,766;1,422;0;3,344;
1.6) By origin of the funds: Foreign funds;94,197;62,723;5,369;26,106;
Purchase of R&D services in biotechnology (thousands of euros);120,281;102,804;9,714;7,763;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;69,564;57,335;8,455;3,773;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;50,718;45,469;1,259;3,990;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;45;52;42;35;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12;9;17;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;16;14;20;18;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;14;14;16;12;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;16;16;20;14;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;18;20;18;16;
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;15;15;18;15;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;39;38;32;
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;52;54;56;46;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;20;20;21;20;
% Companies that have requested biotechnology patents;15;21;11;7;
Number of patents requested;681;485;100;96;
% Companies with income of an international origin related to biotechnological activities;24.3;34.1;12.6;13.5;
% Turnover representing income of an international origin related to biotechnological activities;1.00;9.00;0.00;1.00;
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;59.60;60.20;79.30;54.70;
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;40.40;39.80;20.70;45.40;
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;80.40;78.50;17.90;96.80;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;16.50;19.30;0.60;1.40;
% Income of an international origin related with activities according to the classification: Operating source abroad;2.20;1.30;70.40;1.80;
% Income of an international origin related with activities according to the classification: Other;0.90;0.90;11.10;0.00;
Notes:
1) '.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Source: National Statistics Institute